Navigation Links
St. Jude identifies genomic causes of a certain type of leukemia relapse
Date:11/27/2008

Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to designing treatments for ALL relapse in children and, ultimately, in adults.

The most common childhood cancer, ALL affects thousands of children annually in the United States. Although more than 80 percent of ALL cases are cured, relapse is a significant problem, with only 30 percent of children with relapsed ALL surviving.

Previous studies had found some evidence for genetic differences between the cancer cells of ALL patients at initial diagnosis and those who relapsed. That information was limited, and there had never been a broad comparison of the entire genomes of ALL at initial diagnosis and at subsequent relapse.

In the study that appears in the Nov. 28, 2008, issue of the journal Science, St. Jude researchers compared the genomes of the cancer cells of 61 childhood ALL patients when they were initially diagnosed and after they had relapsed. The investigators used millions of genetic markerscharacteristic genetic variations called single nucleotide polymorphismsas guideposts to pinpoint genetic changes characteristic of relapsed cells. Using these genetic markers, the researchers analyzed all of the cells' chromosomes to look for genetic changes called copy number abnormalities specific to relapsed cells. These changes are considered a major type of damaging gene alterations in ALL.

"In more than 90 percent of the cases, we found differences in the genetic alterations present at the time of diagnosis and at the time of relapse," said Charles Mullighan, M.D., Ph.D., assistant member in the St. Jude Department of Pathology and the paper's first author. "Examining the new changes that are arising at relapse tells us a lot about the individual genetic lesions that might confer resistance to treatment
'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. LSUHSC research identifies key contributor to Alzheimers disease process
2. Pitt research identifies new target in brain for treating schizophrenia
3. Research identifies type of vaccine that holds promise in protecting against TB
4. Conaway Lab identifies novel mechanism for regulation of gene expression
5. HPV DNA test identifies cervical pre-cancerous disease in developing countries with 90% success rate
6. New method identifies meth hot spots
7. Study identifies changes to DNA in major depression and suicide
8. UCLA study identifies mechanism behind mind-body connection
9. International team identifies 21 new genetic risk factors for Crohns disease
10. Stowers Institutes Shilatifard Lab identifies new role for factor critical to transcription
11. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
(Date:10/14/2014)... fly genome for the first time, revealing robust immune ... thrives in pathogen-rich dung piles and garbage heaps. , ... Genome Biology , will increase understanding of house fly ... to resist insecticides, which could lead to novel control ... transmit more than 100 human and animal diseases, including ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2
... Jan. 13, 2011 Genomic research could help doctors ... patients, according to a study by Genomic Health Inc. (Nasdaq: ... drug, oxaliplatin, is widely used in colon cancer. It is ... are likely to recur. It is also used in advanced ...
... and Hyde relationship with mercury, but researchers at the ... a discovery that ultimately could help explain the split ... aquatic environments make methylmercury, a more toxic form of ... nature and other types of bacteria can transform methylmercury ...
... Middle schools soon might add fast cafeteria lines to ... according to Penn State researchers. The U.S. Department of ... to Amit Sharma, assistant professor; Martha Conklin, associate professor, ... health sciences, College of Medicine. The project will use ...
Cached Biology News:TGen and Genomic Health Inc. discover genes affecting cancer drug 2Natural dissolved organic matter plays dual role in cycling of mercury 2Quick school cafeteria lines could lead to healthier food choices 2
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... Calif., March 31 Watson Pharmaceuticals, Inc. (NYSE: ... today that the United States District Court for the ... of Concerta (methylphenidate hydrochloride extended-release tablets) does not infringe ... that the ,373 Patent is invalid. The opinion, ...
... One of the nation,s leading independent research institutes ... align to support the critical mission of protecting the ... solutions. , , Officials at ... expanding MRI,s existing operations by establishing a wholly owned ...
... process platform intended to meet the needs of the Obama ... ... Aliso Viejo, California (PRWEB) March 29, 2009 -- Applied Technology ... BodySensor™ and BodyBalance™ system from its new Digital Data ...
Cached Biology Technology:Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid 2Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors 2Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors 3Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors 4Company to Provide Technology Platform for Digital Data Collection of Computerized Patient Records 2
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
...
Request Info...
...
Biology Products: